Sign in
ASMB Stock Price, Chart, Stats & News
Assembly Biosciences Inc
Save
407.18M
Market cap
–
Current P/E
14.29x
Forward P/E
ASMB chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 77.65% |
Operating margin | -16.76% |
Pretax margin | -8.47% |
Net margin | -8.47% |
Effective tax rate | – |
ROA | -2.38% |
ROE | -5.63% |
D/E | 0.01x |
Interest coverage ratio | – |
ASMB valuation
P/E | – |
P/S | 6.08x |
P/B | 1.50x |
P/CF | -7.56x |
P/FCF | -10.68x |
P/OCF | -7.56x |
PEG | -0.65x |
EV multiple | -48.07x |
About
Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV. The company's development pipeline also features ABI-H3733, which has finished Phase 1a clinical studies, and ABI-4334, currently in pre-clinical assessment for HBV treatment.
Similar securities
Based on sector and market capitalization
Report issue